Noven Announces Availability of Briefing Documents For Daytrana™ Advisory Committee Meeting

-- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) confirmed today that the U.S. Food and Drug Administration (FDA) has posted briefing documents on its website (www.fda.gov) for the Psychopharmacologic Drugs Advisory Committee meeting to be held December 2, 2005 relating to Daytrana™ (methylphenidate transdermal system).

Daytrana™, licensed globally to Shire Pharmaceuticals Group plc, is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years.

Documents posted on the FDA website include materials submitted by Noven and Shire as well as FDA materials.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire Pharmaceuticals Group plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See www.noven.com for additional information.

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
305-253-1916